Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 224.03M P/E - EPS this Y 57.10% Ern Qtrly Grth -47.40%
Income -25.09M Forward P/E -9.21 EPS next Y 250.00% 50D Avg Chg -9.00%
Sales 115.78M PEG -0.25 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book N/A EPS next 5Y 70.00% 52W High Chg -37.00%
Recommedations 2.50 Quick Ratio 1.64 Shares Outstanding 175.40M 52W Low Chg 93.00%
Insider Own 2.11% ROA -10.73% Shares Float 146.96M Beta 0.98
Inst Own 61.38% ROE - Shares Shorted/Prior 5.01M/3.74M Price 1.29
Gross Margin 72.68% Profit Margin -21.67% Avg. Volume 2,107,537 Target Price 4.57
Oper. Margin 5.23% Earnings Date Apr 30 Volume 1,422,371 Change -3.01%
About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals, Inc. News
04/12/24 Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
04/10/24 Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04/04/24 Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
03/12/24 Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
03/07/24 Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year
03/07/24 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript
03/06/24 Q4 2023 Rigel Pharmaceuticals Inc Earnings Call
03/06/24 Owning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),
03/05/24 Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
03/05/24 Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
02/28/24 OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
02/27/24 Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
02/22/24 Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
02/19/24 Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
01/15/24 When Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Become Profitable?
01/08/24 Rigel Pharmaceuticals Provides Business Update
01/04/24 Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
01/03/24 Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
01/03/24 Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
01/02/24 Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
RIGL Chatroom

User Image MaxKlim Posted - 5 hours ago

$RIGL https://www.onclive.com/view/olutasidenib-elicits-durable-remissions-with-without-azacitidine-in-idh1-mutant-mds

User Image GO_DAWGS Posted - 11 hours ago

$RIGL https://www.cancernetwork.com/view/olutasidenib-yields-enduring-remissions-in-previously-treated-idh1-aml

User Image Bliminated Posted - 13 hours ago

$RIGL in. 1.13, no compromises.

User Image kokooo Posted - 13 hours ago

$RIGL 16:02:47 $1.16 534 16:02:47 $1.16 100 16:02:47 $1.16 72 16:02:47 $1.15 28 16:02:16 $1.13 138 16:01:55 $1.13 1,786 16:01:47 $1.13 664 16:01:44 $1.13 5,471 16:00:06 $1.13 2,314,815

User Image Bsbl Posted - 14 hours ago

$RIGL 180k shares in last 2 minutes. Then 2.3 million minute after hours.

User Image Berakhot Posted - 14 hours ago

$RIGL @DBales26 you keeping up with this? Assume u r...

User Image Berakhot Posted - 14 hours ago

$RIGL oh yeah... back in aggressive mode. Profit secured. Holding rest LONG under $1.

User Image RallyRaider Posted - 18 hours ago

$RIGL https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx LOOKS GREAT under 2$ data went over the markets head?

User Image noproetu Posted - 18 hours ago

$RIGL the big boys told Raul to push the shit down with the fake reverse, split FUD… Surprise surprise the patent will resolve positively, earnings will be positive, and this will finally be allowed to pump over three bucks, the MM's have collected when it's low

User Image Springsman72 Posted - 19 hours ago

$RIGL Hopefully get a little positive news or foreshadowing of the copywrite trial today...I believe there's a minor hearing/statements today IIRC.

User Image firepit100 Posted - 1 day ago

$RIGL I still find it odd that Raul has been the only executive to purchase shares, particularly since acquiring at a decimated share price would seem to be a no-brainer for other executives who presumably believe they are doing a bang-up job with running the company. And, coupled with the fact that the board of directors continues to protect him rather than concerning themselves with shareholder value, I’m starting to wonder about Raul’s purchase. The recent announcement about the RS, as well as management’s insistence on pushing for approval even if it is voted down, doesn’t seem to jive with such a substantial investment on Raul’s part. Unless, of course, he isn’t as personally concerned as retail shareholders? In other words, maybe he didn’t cough up his hard-earned money. I could be wrong, but Article XIV of the Rigel Bylaws certainly has me wondering. That article suggests that the board is basically free to dictate the terms of loans to officers.

User Image JA_Animalia Posted - 3 days ago

$RIGL I'll buy mine in the $0.90s on Monday......🤣🤣🤣🤣🤣🤣

User Image kokooo Posted - 3 days ago

$RIGL got 4200 shares at 1.025 at 2.41pm ,got scared for sec when drop to 1.01

User Image Cloud875 Posted - 3 days ago

$RIGL huh 81mm shares after hours

User Image Cloud875 Posted - 3 days ago

$RIGL maybe they’ll change there stance of a potential RS and this jumps to $1.50

User Image DosGatos Posted - 3 days ago

$RIGL when peeps start writing desperate fake letters to the BOD on here that usually signals the end! Yikes!!

User Image Cloud875 Posted - 3 days ago

$RIGL think the split is geared towards getting more interest in the investment community with a higher share price given the positive growth/ break even/ profitability. the next few quarters with contd growth would get the share price over $3

User Image GenralZod Posted - 3 days ago

$RIGL I am concerned that this split concept is brought forth due to the possible belief or knowledge that the Annora case could side against Rigel. Most certainly the pps would drop below $1 for ,maybe, forever? is there a ruling due april 22?

User Image DosGatos Posted - 4 days ago

$RIGL but but but but breakeven!

User Image Bsbl Posted - 4 days ago

$RIGL so we will see what they say at this point.

User Image Bsbl Posted - 4 days ago

$RIGL 9. Will board agree that no issuance of stock to raise money for 3 years if stock split passes? 10. Has company filed complaint with SEC for obvious stock manipulation? Warmly, Chris Helstrom

User Image Bsbl Posted - 4 days ago

$RIGL 1. Has the board or management had conversations with institutions or funds leading up to vote where non public information has been shared? 2. With reverse split, why were additional options offered to management and board? (Not a good look) 3. Will all past options be reduced like stock split if it passes? 4. Should all board and management options be halted for 3-4 years if split happens? 5. With amount of stockholders value destruction during Raul’s tenure building a research bio company, why is he right ceo for a licensing company? 6. Should each board member be required to invest 100k publicly to be member of the board? Would show commitment and belief in company! 7. Why does a 140 million dollar company need a CEO and 7 vice presidents? I ran a 145 million dollar company where I was co president with a CFO and no vice presidents. We made money! 8. What metrics has board put together to measure Raul’s success or failure?

User Image Bsbl Posted - 4 days ago

$RIGL I was happy to see 9 months ago management speaking to expense control and fiscal discipline. We have had two good quarters and with 2-3 more I believe the stock would have been in the $3 range due to continued sales improvement and profitability, taking away the need to raise money thru stock offerings. Then the yearly meeting draft comes out asking for a reverse stock splits. In addition an ask that if reverse split fails the right to look for more votes to overturn people who voted on time. That is offensive. I have come up with a list of questions I would like answered by board at annual meeting which I am happy to travel to if you will not agree to answer this list of questions via email?

User Image Bsbl Posted - 4 days ago

$RIGL Cc: Kamel Ali-Jackson Alison l. Hannah Brian l. Kotzin Gregg a. Lapointe Gary a. Lyons Walter h. Moos Raul r. Rodriguez Jane Wassman Ray Furey Dean Schorno Dear Board, My name is Chris Helstrom and I own one million shares of Rigel. I have been a shareholder of Rigel for about three years. I am part of a group that from what I can tell owns roughly 8-12 million shares. After 2 plus years of trying to communicate to management thru different points. Dean Schorno along with Ray Furey reached out for a video conference which I appreciated. Many of the people I communicate with do not believe Rigel has an investor relations department which alone is something that needs to be dealt with

User Image Bsbl Posted - 4 days ago

$RIGL my response Mr. Furey, Thanks for the response and I do appreciate the time we spent talking. To say that your response to stockholders has been excellent is laughable. The group I converse with about rigel has 8 to 10 million shares and many truly do not believe that Rigel has an investor relations department. As I did not until our conversations that happened only after I had tried to access any point of communication including leaving multiple voice mails for Raul who never responded. I have records for all. It is time for Rigel to start understanding their fiduciary duties to stockholders!!!! I will want to know if company has shared any non public information with institutions leading up to this vote. Warmly, Chris

User Image Bsbl Posted - 4 days ago

$RIGL it promptly and post it on Rigel’s website. Persons interested in communicating with the independent directors regarding their concerns or issues may address correspondence to a particular director, or to the independent directors generally, in care of Legal Department, Rigel Pharmaceuticals, Inc. at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080. If no particular director is named, letters will be forwarded, depending on the subject matter, to the Chair of the Audit, Compensation, Finance or Corporate Governance, Health Care Compliance Oversight and Nominating Committee. Sincerely, Ray Ray Furey EVP, General Counsel and Corporate Secretary Rigel Pharmaceuticals 415.940.3932 cell

User Image Bsbl Posted - 4 days ago

$RIGL Hello Chris: You may send a communication to Rigel’s physical address, see instructions below from the proxy, care of a specific director or to the Board generally. Stockholder Communications with the Board of Directors To date, Rigel has not adopted a formal process related to stockholder communications with the Board. Nevertheless, every effort has been made to ensure that the views of stockholders are heard by the Board or individual directors, as applicable, and that appropriate and timely responses are provided to stockholders. We believe our responsiveness to stockholder communications to the Board has been excellent. If a formal process for stockholder communications with the Board is adopted, we will publish it

User Image GenralZod Posted - 4 days ago

$RIGL

User Image Bsbl Posted - 4 days ago

$RIGL Hello, This is Chris helstrom. A stockholder of Rigel and we had a conference call last fall. Can you please forward on a list of board members with their addresses so I can send a letter to them. Two quarters of progress and now a reverse split while the company throws out more options is unbelievable. Then to ask for more time if the reverse split is voted down to gin up votes is offensive. I now have one million shares and it is time for this board to actually start listening to shareholders as that is part of their fiduciary responsibility. Warmly, Chris My message to Rigel today. We will see the response. Sent to ray furey who is chief legal officer. I assume he will respond as it is his job to.

User Image Berakhot Posted - 4 days ago

$RIGL Out shares above $1 after rejection on Daily 50ema. Took profit on downtrend at lower highs but regret holding to long. Small-cap Bios usually at mercy of Whales, need cash infusion. Did not "think" of R/s for RIGL after 3 FDA drugs. Thought it safely made it thru shark infested waters after 3 Bottoms. Higher Low/higher High in March seemed to be upward trend. Then door closed. I did think ~170Mshrs was problem at times. But failed to transfer thoughts into aggressive action. Lesson: 1) take more profit at highs. Seems easy, 2) but overthinking or greed causes profit loss. 3) stick to profit taking on regular basis. Allowed Long trade to lull me to sleep instead of aggressive chart analysis. Lost decent profits off highs, trading less than before. Lost edge from original entry of RIGL. Appreciate this Board, shared ideas, insights by all. Remain Long under $1. Pivot on Daily today. Not sure if it holds after downtrend under 200ma. Weekly chart...

Analyst Ratings
Citigroup Buy Mar 7, 24
Cantor Fitzgerald Neutral Mar 6, 24
HC Wainwright & Co. Buy Mar 6, 24
B. Riley Securities Neutral Mar 6, 24
HC Wainwright & Co. Buy Feb 22, 24
HC Wainwright & Co. Buy Jan 4, 24
HC Wainwright & Co. Buy Dec 8, 23
HC Wainwright & Co. Buy Aug 2, 23
HC Wainwright & Co. Buy May 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Santos David A EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 02 Sell 1.14 14,519 16,552 349,093 02/06/24
Schorno Dean L EVP & Chief Financia.. EVP & Chief Financial Officer Feb 02 Sell 1.13 12,628 14,270 402,891 02/06/24
RODRIGUEZ RAUL R CEO, President CEO, President Feb 02 Sell 1.14 52,894 60,299 2,036,629 02/06/24
RODRIGUEZ RAUL R CEO, President CEO, President Jun 09 Buy 0.6884 1,000,000 688,400 1,391,776 06/13/22